CO6150195A2 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
CO6150195A2
CO6150195A2 CO09024629A CO09024629A CO6150195A2 CO 6150195 A2 CO6150195 A2 CO 6150195A2 CO 09024629 A CO09024629 A CO 09024629A CO 09024629 A CO09024629 A CO 09024629A CO 6150195 A2 CO6150195 A2 CO 6150195A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
fat
substance
oil
active ingredient
Prior art date
Application number
CO09024629A
Other languages
English (en)
Inventor
Yukihiro Nomura
Muneo Nonomura
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CO6150195A2 publication Critical patent/CO6150195A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Una composición farmacéutica sólida, caracterizada porque comprende un ingrediente activo, una sustancia similar a grasa y aceite que tiene un punto de fusión bajo y una sustancia aglutinante de viscosidad baja. 2.- La composición de conformidad con la reivindicación 1, caracterizada porque el ingrediente activo es un compuesto cristalino pobremente soluble. 3.- La composición de conformidad con la reivindicación 2, caracterizada porque el compuesto cristalino pobremente soluble tiene un punto de fusión de aproximadamente 75°C -aproximadamente 250°C y una solubilidad en agua no mayor que aproximadamente 1 g/L. 4.- La composición de conformidad con la reivindicación 2, caracterizada porque el compuesto cristalino pobremente soluble es un compuesto representado por la fórmula (I):en donde el anillo W es un residuo heterocíclico que contiene N sustituido opcionalmente; R3 es un grupo capaz de formar un anión o un grupo convertible al mismo; X es un enlace directo o un separador que tiene una longitud atómica de dos o menos entre el grupo fenileno y el grupo fenilo; y N es un número entero de 1 ó 2 o una sal del mismo. 5.- La composición de conformidad con la reivindicación 4, caracterizada porque el compuesto representado por la fórmula (I) o una sal del mismo es el ácido 2-etoxi-1-{[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1H-bencimidazol-7-carboxílico. 6.- La composición de conformidad con la reivindicación 1, caracterizada porque la sustancia similar a grasa y aceite tiene un punto de fusión de 20°C - 90°C.
CO09024629A 2006-08-10 2009-03-10 Composicion farmaceutica CO6150195A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006218145 2006-08-10

Publications (1)

Publication Number Publication Date
CO6150195A2 true CO6150195A2 (es) 2010-04-20

Family

ID=39033098

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09024629A CO6150195A2 (es) 2006-08-10 2009-03-10 Composicion farmaceutica

Country Status (25)

Country Link
US (1) US20100016382A1 (es)
EP (1) EP2058010B1 (es)
JP (2) JP5361188B2 (es)
KR (1) KR101464007B1 (es)
CN (3) CN102813635A (es)
AT (1) ATE555777T1 (es)
AU (1) AU2007282400B2 (es)
BR (1) BRPI0716030A2 (es)
CA (1) CA2660427A1 (es)
CO (1) CO6150195A2 (es)
CR (1) CR10632A (es)
EA (1) EA016728B1 (es)
ES (1) ES2382902T3 (es)
GE (1) GEP20125420B (es)
HK (1) HK1133817A1 (es)
IL (1) IL196853A0 (es)
MA (1) MA30759B1 (es)
MX (1) MX2009001429A (es)
MY (1) MY147310A (es)
NO (1) NO20090759L (es)
NZ (1) NZ574954A (es)
TN (1) TN2009000042A1 (es)
UA (1) UA96302C2 (es)
WO (1) WO2008018569A1 (es)
ZA (1) ZA200901075B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006083A2 (en) 2006-07-07 2008-01-10 Surmodics, Inc. Beaded wound spacer device
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
NZ590948A (en) * 2008-07-31 2012-06-29 Takeda Pharmaceutical Solid pharmaceutical composition comprising a diuretic, ph control agent and an oxadiazole
KR101316653B1 (ko) * 2011-05-19 2013-10-10 한미정밀화학주식회사 헤테로고리 화합물의 제조방법
KR101275092B1 (ko) * 2011-05-19 2013-06-17 한미정밀화학주식회사 아질사르탄의 개선된 제조방법
KR20140030237A (ko) * 2011-05-23 2014-03-11 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤즈이미다졸 유도체를 함유하는 고체 약제학적 조성물
CN103113364B (zh) * 2012-08-27 2015-11-18 南京华威医药科技开发有限公司 阿齐沙坦多晶型的制备方法
CN103705510A (zh) * 2013-12-27 2014-04-09 华润赛科药业有限责任公司 一种阿齐沙坦固体组合物的制备方法
US10201457B2 (en) 2014-08-01 2019-02-12 Surmodics, Inc. Wound packing device with nanotextured surface
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6895779B2 (ja) * 2017-03-17 2021-06-30 東和薬品株式会社 アジルサルタン含有固形医薬組成物
CN109223723B (zh) * 2017-07-11 2021-08-27 南京华威医药科技集团有限公司 吡非尼酮片剂及其制备方法和用途
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
WO2019246503A1 (en) 2018-06-22 2019-12-26 Ideaz, Llc Diphenyl tablets and methods of preparing the same
CN111617046A (zh) * 2020-07-09 2020-09-04 浙江诺得药业有限公司 阿齐沙坦分散片及其制备工艺
CN115531350B (zh) * 2022-11-03 2024-01-05 珠海润都制药股份有限公司 一种阿齐沙坦胶囊及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01308231A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
CA2017916C (en) * 1989-06-07 1999-02-02 Minoru Aoki Etoposide preparations
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
JP2682353B2 (ja) * 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
TW284688B (es) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
DE69322764T2 (de) * 1992-10-09 1999-05-06 Kanegafuchi Chemical Ind Herstellungsmethode für feines granulat
CN1044088C (zh) * 1992-11-13 1999-07-14 武田药品工业株式会社 口服药物组合物及制备方法
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
JPH1135451A (ja) * 1994-07-27 1999-02-09 Yamanouchi Pharmaceut Co Ltd 口腔内溶解型錠剤およびその製造方法
BR9908474A (pt) * 1998-03-04 2000-12-05 Takeda Chemical Industries Ltd Preparação de liberação prolongada, processo para a produção de uma preparação de liberação prolongada, e, composição farmacêutica
JPH11315034A (ja) * 1998-03-04 1999-11-16 Takeda Chem Ind Ltd アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途
DK1736144T3 (en) * 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
JP2000053563A (ja) * 1998-08-07 2000-02-22 Bayer Yakuhin Ltd 苦味がマスクされた速放性細粒剤
MXPA05007883A (es) * 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
CN1761465B (zh) * 2003-01-29 2010-10-13 武田药品工业株式会社 制备被覆制剂的方法
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
JP2006218145A (ja) 2005-02-14 2006-08-24 My Kk キャリーバッグ
KR20080027783A (ko) * 2005-06-22 2008-03-28 다케다 야쿠힌 고교 가부시키가이샤 난용성 활성 성분을 함유하는 정제

Also Published As

Publication number Publication date
MX2009001429A (es) 2009-02-17
EA016728B1 (ru) 2012-07-30
AU2007282400B2 (en) 2012-08-30
CN101528262A (zh) 2009-09-09
NZ574954A (en) 2011-11-25
WO2008018569A1 (fr) 2008-02-14
CN102813635A (zh) 2012-12-12
MA30759B1 (fr) 2009-10-01
IL196853A0 (en) 2009-11-18
ZA200901075B (en) 2010-05-26
HK1133817A1 (en) 2010-04-09
ATE555777T1 (de) 2012-05-15
MY147310A (en) 2012-11-30
NO20090759L (no) 2009-03-11
JPWO2008018569A1 (ja) 2010-01-07
CA2660427A1 (en) 2008-02-14
JP2011168622A (ja) 2011-09-01
EP2058010A4 (en) 2009-09-30
JP5361188B2 (ja) 2013-12-04
CN103610673A (zh) 2014-03-05
TN2009000042A1 (en) 2010-08-19
AU2007282400A1 (en) 2008-02-14
EP2058010A1 (en) 2009-05-13
UA96302C2 (en) 2011-10-25
GEP20125420B (en) 2012-03-26
CR10632A (es) 2009-04-14
BRPI0716030A2 (pt) 2013-07-30
EA200970188A1 (ru) 2009-08-28
US20100016382A1 (en) 2010-01-21
ES2382902T3 (es) 2012-06-14
EP2058010B1 (en) 2012-05-02
KR20090050071A (ko) 2009-05-19
KR101464007B1 (ko) 2014-11-20

Similar Documents

Publication Publication Date Title
EA200970188A1 (ru) Фармацевтическая композиция
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
FR2851470B1 (fr) Composition pharmaceutique pour administration transdermique ou transmuqueuse
ATE439123T1 (de) Verwendung von emulsionen zur intra- und periocularen injection
ZA200702536B (en) Low oil emulsion compositions for delivering taxolds and other insoluble drugs
EA200501702A1 (ru) Устойчивая к манипуляциям дозировочная форма для трансдермального введения
NO20090175L (no) Stabile laquinimod sammensetninger
EA200870060A1 (ru) Эмульсия бутилфталида для внутривенного введения и ее применение
CL2007003265A1 (es) Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras.
BRPI0515991A (pt) derivados de bisariluréia substituìda heterocìclica como inibidores de cinase
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
TW200616616A (en) Paclitaxel aqueous injection solution and methods for preparing the same
EA201170512A1 (ru) Композиция для перорального введения
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
WO2008081829A1 (ja) 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーｅ
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
MA28603B1 (fr) Composition pharmaceutique antimycobacterienne
DE602006012962D1 (de) Pharmazeutische Zubereitungen von Ciprofloxacin
DK1976538T3 (da) Farmaceutisk formulering til behandling af slidgigt indeholdende clodronsyre og hyaluronsyre
DK1617827T3 (da) Farmaceutisk sammensætning i form af en hydrogel til den transdermale administration af aktivstoffer
EA200500672A1 (ru) Содержащие альфузозин композиции с отсроченным высвобождением
ATE487492T1 (de) Pharmazeutische zusammensetzung zur behandlung von drogenabhängigkeit
WO2011128628A3 (en) Gelled oral pharmaceutical compositions